Caricamento...
A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) often suffer from progressive disease despite previous therapy. It has been a great challenge for those patients. In 2012, regorafenib was approved for mCRC. In this meta-analysis, we aimed to collect and present existing data to exploret...
Salvato in:
| Pubblicato in: | Medicine (Baltimore) |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Health
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6200445/ https://ncbi.nlm.nih.gov/pubmed/30290640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000012635 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|